Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Saizen

- PMLiVE

Merck’s digital health accelerator expands into Africa

Will run new startup support programme in Nairobi

- PMLiVE

Merck KGaA adds two to its executive board

Appoints Udit Batra and Walter Galinat, while Bernd Reckmann will retire

- PMLiVE

Germany’s Merck triumphs in court battle with US namesake

English court rules Merck & Co breached the firms' naming agreement

- PMLiVE

Syndax teams with Merck/Pfizer on immuno-oncology combo

Oral cancer drug entinostat to test with avelumab

- PMLiVE

Merck abandons evofosfamide as two trials fail

Solid tumour candidate underwhelms in phase III studies

- PMLiVE

FDA deems Merck KGaA and Pfizer’s avelumab a breakthrough

Could become first-in-class treatment for Merkel cell carcinoma

CAR-T cancer therapy passes milestone

Belgianbiotech Celyad's cancer immunotherapy will now be tested at higher doses

- PMLiVE

Merck KGaA and Pfizer move avelumab into late-stage trials

Begin phase III studies of the monoclonal antibody in lung cancer

- PMLiVE

Merck appoints new senior vice president

Laszlo Radvanyi joinsthe firm

- PMLiVE

Merck names new CEO and rebrands under one name

New logo and appointment of Stefan Oschmann from next year

- PMLiVE

FDA fast-tracks Merck/Pfizer’s rare skin cancer drug avelumab

Comes a month after drug was given orphan status

- PMLiVE

Merck takes novel immuno-oncology drug into clinical trials

Potential to offer alternative to anti-PD-1/anti-PDL1 immunotherapies 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links